Usón J, Balsa A, Pascual-Salcedo D, Cabezas J A, Gonzalez-Tarrio J M, Martín-Mola E, Fontan G
Rheumatology Unit, Hospital Universitario La Paz, Madrid, Spain.
J Rheumatol. 1997 Nov;24(11):2069-75.
We studied interleukin 6 (IL-6) and soluble IL-6 receptor (sIL-6R) in serum and synovial fluid (SF) to investigate their role in different arthropathies.
IL-6 was measured by ELISA and bioassay and sIL-6R by ELISA, in 210 sera and 73 SF samples from 49 patients with rheumatoid arthritis (RA), 20 crystal deposition disease, 17 osteoarthritis (OA), 24 with other inflammatory arthropathies, and 100 controls. In all patients, disease activity was assessed by erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP); in patients with RA and other arthropathies pain, tender and swollen joints, and Ritchie index were also evaluated. Total leukocyte count in SF was determined.
There was good correlation between IL-6 ELISA and bioassay levels both in serum (r = 0.62, p = 0.0001) and in SF (r = 0.72, p = 0.0001). Serum IL-6 was detected only in patients with inflammatory arthritis and SF IL-6 was detected in all patient groups. Serum IL-6 correlated with swollen joints (r = 0.35, p = 0.05), ESR (r = 0.46, p = 0.001), and CRP (r = 0.46, p = 0.001) in RA; and with CRP (r = 0.89, p = 0.0001) in crystal deposition disease. SF IL-6 correlated with ESR (r = 0.54, p = 0.007) and CRP (r = 0.42, p = 0.04) in RA; with SF total leukocyte count (r = 0.61, p = 0.004) in crystal deposition disease; and with SF total leukocyte count (r = 0.61, p = 0.009) in OA. No correlations were found in the group with other inflammatory diseases. No correlations were found between sIL-6R and IL-6 or between sIL-6R and disease activity variables in any group of patients.
Unlike IL-6, sIL-6R is not produced at the site of inflammation and is not related to clinical or biological disease activity variables. Only in RA are both IL-6 and sIL-6R levels increased, suggesting that sIL-6R may reinforce the systemic effects of IL-6.
我们研究了血清和滑液（SF）中的白细胞介素6（IL-6）和可溶性IL-6受体（sIL-6R），以探讨它们在不同关节病中的作用。
采用酶联免疫吸附测定（ELISA）和生物测定法检测49例类风湿关节炎（RA）患者、20例晶体沉积病患者、17例骨关节炎（OA）患者、24例其他炎性关节病患者以及100例对照者的210份血清和73份SF样本中的IL-6，采用ELISA法检测sIL-6R。对所有患者，通过红细胞沉降率（ESR）和C反应蛋白（CRP）评估疾病活动度；对RA和其他关节病患者，还评估了疼痛、压痛和肿胀关节以及里奇指数。测定SF中的白细胞总数。
血清和SF中IL-6的ELISA水平与生物测定水平之间均具有良好的相关性（血清中r = 0.62，p = 0.0001；SF中r = 0.72，p = 0.0001）。仅在炎性关节炎患者中检测到血清IL-6，而在所有患者组中均检测到SF IL-6。在RA中，血清IL-6与肿胀关节（r = 0.35，p = 0.05）、ESR（r = 0.46，p = 0.001）和CRP（r = 0.46，p = 0.001）相关；在晶体沉积病中与CRP（r = 0.89，p = 0.0001）相关。在RA中SF IL-6与ESR（r = 0.54，p = 0.007）和CRP（r = 0.42，p = 0.04）相关；在晶体沉积病中与SF白细胞总数（r = 0.61，p = 0.004）相关；在OA中与SF白细胞总数（r = 0.61，p = 0.009）相关。在其他炎性疾病组中未发现相关性。在任何患者组中，均未发现sIL-6R与IL-6之间或sIL-6R与疾病活动度变量之间存在相关性。
与IL-6不同，sIL-6R并非在炎症部位产生，且与临床或生物学疾病活动度变量无关。仅在RA中IL-6和sIL-6R水平均升高，提示sIL-6R可能增强IL-6的全身效应。
